214 related articles for article (PubMed ID: 24461080)
1. Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.
Martinez D; Palmer C; Simar D; Cameron BA; Nguyen N; Aggarwal V; Lloyd AR; Zekry A
Liver Int; 2015 Feb; 35(2):463-72. PubMed ID: 24461080
[TBL] [Abstract][Full Text] [Related]
2. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
[TBL] [Abstract][Full Text] [Related]
3. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.
Meng P; Zhao S; Niu X; Fu N; Su S; Wang R; Zhang Y; Qiao L; Nan Y
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428948
[TBL] [Abstract][Full Text] [Related]
5. T helper type 1/T helper type 17-related cytokines in chronic hepatitis C patients before and after interferon and ribavirin therapy.
Fathy A; Ahmed AS; Metwally L; Hassan A
Med Princ Pract; 2011; 20(4):345-9. PubMed ID: 21576995
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin.
Ueyama M; Nakagawa M; Sakamoto N; Onozuka I; Funaoka Y; Watanabe T; Nitta S; Kiyohashi K; Kitazume A; Murakawa M; Nishimura-Sakurai Y; Sekine-Osajima Y; Itsui Y; Azuma S; Kakinuma S; Watanabe M;
Antivir Ther; 2011; 16(7):1081-91. PubMed ID: 22024524
[TBL] [Abstract][Full Text] [Related]
7. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
Huang Y; Feld JJ; Sapp RK; Nanda S; Lin JH; Blatt LM; Fried MW; Murthy K; Liang TJ
Gastroenterology; 2007 Feb; 132(2):733-44. PubMed ID: 17258724
[TBL] [Abstract][Full Text] [Related]
8. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
9. The role of IL-28, IFN-γ, and TNF-α in predicting response to pegylated interferon/ribavirin in chronic HCV patients.
Abdou AG; Asaad NY; Ehsan N; Eltahmody M; El-Sabaawy MM; Elkholy S; Elnaidany NF
APMIS; 2015 Jan; 123(1):18-27. PubMed ID: 25131720
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
11. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.
Zhang L; Hao CQ; Miao L; Dou XG
Genet Mol Res; 2014 Nov; 13(4):9747-55. PubMed ID: 25501184
[TBL] [Abstract][Full Text] [Related]
12. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Huang JF; Huang CF; Yu ML; Dai CY; Huang CI; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Chuang WL
J Gastroenterol Hepatol; 2011 Mar; 26(3):530-5. PubMed ID: 21332548
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C.
He Q; Graham CS; Durante Mangoni E; Koziel MJ
Liver Int; 2006 Nov; 26(9):1100-10. PubMed ID: 17032411
[TBL] [Abstract][Full Text] [Related]
14. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Dill MT; Makowska Z; Duong FHT; Merkofer F; Filipowicz M; Baumert TF; Tornillo L; Terracciano L; Heim MH
Gastroenterology; 2012 Sep; 143(3):777-786.e6. PubMed ID: 22677194
[TBL] [Abstract][Full Text] [Related]
15. Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C.
Araújo AR; Peruhype-Magalhães V; Coelho-dos-Reis JG; Chaves LP; de Lima TA; Pimentel JP; de Paula L; de Almeida CM; Tarragô AM; Tateno A; Levi JE; Teixeira-Carvalho A; Martins-Filho OA; Lira Eda F; Torres KL; Talhari S; Malheiro A
Immunol Lett; 2013; 154(1-2):61-9. PubMed ID: 23973662
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
Pham TN; Lin DM; Mulrooney-Cousins PM; Churchill ND; Kowala-Piaskowska A; Mozer-Lisewska I; Machaj A; Pazgan-Simon M; Zalewska M; Simon K; King D; Reddy SB; Michalak TI
J Med Virol; 2013 Mar; 85(3):441-8. PubMed ID: 23280583
[TBL] [Abstract][Full Text] [Related]
17. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
Wang T; Blatt LM; Seiwert SD
J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
[TBL] [Abstract][Full Text] [Related]
19. Multiple cytokine profiling of the therapeutic responses to ribavirin and pegylated interferon-alpha2b using an "induction" approach with natural interferon-beta in difficult-to-treat chronic hepatitis C.
Kishida Y; Haruna Y; Naitoh M; Katayama K; Kashiwagi T
J Interferon Cytokine Res; 2009 Jun; 29(6):353-68. PubMed ID: 19441887
[TBL] [Abstract][Full Text] [Related]
20. Th1 and Th2 cytokine profiles induced by hepatitis C virus F protein in peripheral blood mononuclear cells from chronic hepatitis C patients.
Yue M; Deng X; Zhai X; Xu K; Kong J; Zhang J; Zhou Z; Yu X; Xu X; Liu Y; Zhu D; Zhang Y
Immunol Lett; 2013 May; 152(2):89-95. PubMed ID: 23680070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
